Clinical Trials Logo

Filter by:
NCT ID: NCT05662020 Active, not recruiting - Clinical trials for Human Papillomavirus Infection

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Start date: March 23, 2022
Phase: Phase 3
Study type: Interventional

The study is to evaluate immune response induced by 9-valent HPV study vaccine is non-inferior to those induced by GARDASIL® 9 administrated with 3-dose schedule in female participants aged 20-26 years in China, if the immune response induced with same conditions in 9-19 age group is non-inferior to 20-26 age group, and if the immune response induced by 9-valent HPV study vaccine administrated with 2-dose schedule in females aged 9-14 years is non-inferior to 3-dose schedule in females aged 20-26 years.

NCT ID: NCT05661955 Recruiting - Melanoma Clinical Trials

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Start date: January 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to assess the overall response rate, evaluate the antitumor activity, and characterize the safety and tolerability of BGB-A445 alone or in combination with tislelizumab in participants With Advanced or Metastatic Urothelial Carcinoma (UC), Renal Cell Carcinoma (RCC), or Melanoma

NCT ID: NCT05661838 Completed - Spinal Fusion Clinical Trials

Effect of Intraoperative Allogeneic Blood Transfusion on Postoperative Pulmonary Complications

Start date: August 1, 2013
Phase:
Study type: Observational

Elective spine surgery is associated with a high incidence of perioperative complications, including peri- and postoperative pulmonary complications (PPCs), which occur in nearly 4% of patients. More than 40% of all deaths after elective spine surgery are attributed to PPCs. However, whether it influences risk of other PPCs is unclear.

NCT ID: NCT05661786 Recruiting - Chronic Hepatitis b Clinical Trials

Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase

PILOT
Start date: December 2022
Phase:
Study type: Observational

Chronic hepatitis B virus (HBV) infection remains a global public health burden around the world. Investigating the disease process of chronic hepatitis B (CHB) is essential to individual management in clinical practice. According to American Association for the Study of Liver Diseases (AASLD) 2018 Hepatitis B Guidance, CHB can be classified into four phases: immune-tolerant CHB, HBeAg-positive immune active CHB, inactive CHB and hepatitis B e antigen (HBeAg)-negative immune active CHB. Antiviral therapy is recommended in patients with HBeAg-positive or -negative immune active CHB patients to reduce the incidence of liver cirrhosis and hepatocellular carcinoma, while periodic monitoring is recommended for inactive carrier and immune-tolerant CHB patients. However, a substantial proportion of patients fall into an indeterminate phase whose serum HBV DNA and alanine aminotransferase levels do not fit well into these well-described phases. Most of CHB patients with indeterminate phase are HBeAg negative. However, the clinical outcomes of these patients remain unclear. Therefore, the purpose of this study is to investigate the clinical outcomes of HBeAg-negative chronic hepatitis B patients with indeterminate phase.

NCT ID: NCT05661591 Completed - Malignant Tumor Clinical Trials

Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects

Start date: February 28, 2023
Phase: Phase 1
Study type: Interventional

The study is being conduct to evaluate fluconazole effect of on SHR2554 in condition of single-canter, open-label, single-dose in healthy subjects. To explore the SHR2554 pharmacokinetics change under use of fluconazole and insure the safety with SHR2554 combined with fluconazole.

NCT ID: NCT05661578 Recruiting - Clinical trials for PD-L1-selected Solid Tumors

A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

SKYSCRAPER-11
Start date: May 4, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, pharmacokinetics, and immunogenicity of tiragolumab and atezolizumab intravenous fixed-dose combination (IV FDC) in participants with histologically confirmed PD-L1-selected solid tumors whose disease is locally advanced, recurrent, or metastatic and for whom an investigational agent in combination with an anti-PD-L1 antibody is considered an acceptable treatment option.

NCT ID: NCT05661357 Active, not recruiting - Colorectal Cancer Clinical Trials

Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression

HCCSC-C03
Start date: January 1, 2023
Phase: Phase 4
Study type: Interventional

Single arm, prospective, exploratory clinical study of Disitamab Vedotin combined with Fruquintinib for advanced colorectal cancer with HER2 expression or mutation that has received at least two standard treatment failures

NCT ID: NCT05661240 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields (EFE-P100)Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1(PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Start date: December 20, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The tumor treating fields(EFE-P100)generates alternating electric field during operation, and the tumor treating fields(EFE-P100)has a specific frequency and a specific field intensity. The tumor treating fields(EFE-P100)patch acts on the corresponding part of the patient and prevents the mitosis of tumor cells. This study was divided into two phases including phase II and phase III clinical trials. The main purpose of phase II clinical trial is to evaluate the safety of tumor treating fields(EFE-P100) combined with docetaxel injection in the second-line treatment of stage IV non-small Cell Lung Cancer (NSCLC) patients who failed after platinum-containing chemotherapy and anti-programmed Death 1(PD-1)/Programmed Cell Death-Ligand 1(PD-L1) antibody treatment. The main purpose of phase III clinical trial is to compare the efficacy of tumor treating fields(EFE-P100) combined with docetaxel injection and docetaxel injection alone in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) patients who failed after platinum-containing chemotherapy and anti-programmed Death 1(PD-1)/Programmed Cell Death-Ligand 1(PD-L1) antibody treatment.

NCT ID: NCT05661227 Recruiting - Clinical trials for Ischemic Reperfusion Injury

Mechanism of Cardiac and Cerebral Function Injury Caused by Intraoperative Limb Ischemia-reperfusion

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

As a simple auxiliary tool for lower extremity orthopedic surgery, tourniquet can effectively reduce intraoperative bleeding and ensure the clarity of the operative field, effectively shorten the operation time and improve the operation efficiency. The extensive use of tourniquets in lower extremity surgery will not only cause local paralysis, pain and other complications, but also bring about postoperative complications such as large drainage volume and deep vein thrombosis. Recent studies have found that tourniquet induced ischemia-reperfusion injury not only affects the local tissue structure and function of skeletal muscle, but also causes reperfusion injury in distant organs (such as heart, lung and brain). Therefore, improving tourniquet ischemia-reperfusion injury after knee replacement is of great significance to improve the quality of life of patients during the perioperative period. Therefore, the aim of this study was to investigate the effects of dexmedetomidine and tourniquet pretreatment on myocardial injury and brain injury caused by lower extremity ischemia-reperfusion.

NCT ID: NCT05661175 Recruiting - Clinical trials for Percutaneous Nephrolithotomy

Application of One-handed Lithotripsy in Percutaneous Nephrolithotomy

Start date: December 3, 2022
Phase: N/A
Study type: Interventional

Percutaneous nephrolithotomy(PCNL) is a surgical method for upper urinary calculi.Traditional percutaneous nephrolithotomy usually requires the lithotripsy with the left hand holding the nephroscope and the right hand adjusting the laser fiber,which requires a lot of practice to master this technique.The goal of this study is to explore the safety and effectiveness of the PCNL with one-handed lithotripsy technique